脂質調整剤の世界市場レポート 2025年

脂質調整剤市場規模は、今後数年間で力強い成長が見込まれます。2029年には102億米ドルに成長し、CAGRは6.9％となります。予測期間の成長は、心血管疾患の有病率の増加、加齢に伴う動脈硬化の発生率の上昇、肥満率の増加、メタボリックシンドロームの有病率の上昇、個別化医療への注目の高まりに起因すると考えられます。予測期間における主要動向には、医薬品開発の進歩、デジタルヘルスソリューションの統合、価値による価格設定モデルの採用、市販薬の需要増加、患者本位の薬剤療法の強化などが含まれます。

心血管疾患の有病率の増加は、今後の狭心症治療市場の拡大を促進すると予想されます。心血管疾患には、冠動脈疾患、高血圧、心不全、脳卒中など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。心血管疾患（CVD）の増加は、人口の高齢化、不健康なライフスタイル、肥満の流行などの要因に起因しています。高コレステロールは、プラークの蓄積により動脈が硬化し狭くなる動脈硬化を引き起こしますが、脂質調整剤はその進行を防ぎ、心臓発作や脳卒中のリスクを軽減する上で重要な役割を果たします。例えば、英国を拠点とする心血管研究の慈善団体である英国心臓財団のデータによると、英国では約760万人が心臓・循環器系疾患に罹患しており、男性約400万人、女性約360万人がこれらの疾患を抱えています。これらの疾患は英国における全死亡の約27％を占め、年間17万人以上、毎日約480人、3分に1人が死亡していることになります。その結果、心血管疾患の有病率の上昇が狭心症治療市場の成長に拍車をかけています。

脂質調整薬市場の主要企業は、心臓疾患のある患者の高い低比重リポタンパク（LDL）コレステロール値に対処するため、先進的な経口脂質低下薬を積極的に開発しています。これらの経口薬は、高コレステロールの原因となる遺伝的異常を持つ患者や心臓病と診断された患者を対象としています。例えば、2022年5月、インドの専門ジェネリック医薬品会社であるサン・ファーマシューティカルインダストリーズ・リミテッドは、心臓病患者の高LDLコレステロール値に対する革新的な治療を提供するためにデザインされた経口薬であるベンペド酸ブリロをインドで発売しました。ベンペド酸は、コレステロール産生に関与する酵素であるATPクエン酸リアーゼを阻害し、肝臓でのコレステロール合成を制御するAMP活性化プロテインキナーゼ（AMPK）を活性化することにより、二重の作用機序を発揮します。1日1回の経口投与により、他のコレステロール低下薬と比較して患者の利便性が向上します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の脂質調整剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脂質調整剤市場：成長率分析
• 世界の脂質調整剤市場の実績：規模と成長、2019～2024年
• 世界の脂質調整剤市場の予測：規模と成長、2024～2029年、2034年
• 世界の脂質調整剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脂質調整剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 脂質調整剤
• 麻薬性鎮痛剤
• アンジオテンシン変換酵素（ACE）阻害剤
• 呼吸器系薬剤
• 利尿剤
• カルシウム拮抗薬
• ホルモン避妊薬
• その他
• 世界の脂質調整剤市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 高コレステロール血症
• 高トリグリセリド血症
• 冠動脈疾患
• その他
• 世界の脂質調整剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射
• 世界の脂質調整剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品
• ワクチンと薬
• 科学研究
• 栄養とサプリメント
• 飲食品
• その他
• 世界の脂質調整剤市場、脂質調節剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• スタチン
• フィブラート
• ナイアシン
• オメガ3脂肪酸
• 世界の脂質調整剤市場、麻薬性鎮痛剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オピオイド鎮痛薬
• 複合鎮痛剤（オピオイドと非オピオイド）
• 鎮痛拮抗薬
• 世界の脂質調整剤市場、アンジオテンシン変換酵素（ACE）阻害剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カプトプリル
• エナラプリル
• リシノプリル
• ラミプリル
• 世界の脂質調整剤市場、呼吸器系薬剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 気管支拡大薬
• コルチコステロイド
• 抗ヒスタミン薬
• 世界の脂質調整剤市場、利尿薬剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• チアジド系利尿薬
• ループ利尿薬
• カリウム保持性利尿薬
• 世界の脂質調整剤市場、カルシウム拮抗薬剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジヒドロピリジン
• 非ジヒドロピリジン
• 世界の脂質調整剤市場、ホルモン避妊薬剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口避妊薬
• 注射避妊薬
• 埋め込み型避妊具
• 世界の脂質調整剤市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ベータ遮断薬
• 抗凝固薬
• 抗血小板薬

第7章 地域別・国別分析

• 世界の脂質調整剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の脂質調整剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脂質調整剤市場：競合情勢
• 脂質調整剤市場：企業プロファイル
  • Pfizer Inc.
  • AbbVie Inc.
  • Bayer AG
  • Sanofi SA
  • AstraZeneca plc

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG
• Amgen Inc.
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Hetero Drugs Limited
• Dr. Reddy's Laboratories Ltd.
• Biocon Ltd.
• Alnylam Pharmaceuticals Inc.
• Amarin Corporation plc
• Arrowhead Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 脂質調整剤市場、2029年：新たな機会を提供する国
• 脂質調整剤市場、2029年：新たな機会を提供するセグメント
• 脂質調整剤市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Lipid regulators, also referred to as lipid-lowering drugs or hypolipidemic agents, are medications utilized to regulate blood lipid levels, specifically cholesterol and triglycerides. These drugs play a crucial role in minimizing the risk of cardiovascular disease, and they also possess anti-inflammatory properties that aid in stabilizing existing plaques and reducing the likelihood of plaque rupture and associated cardiovascular events.

The main types of lipid regulators include narcotic analgesics, angiotensin-converting enzyme (ACE) inhibitors, respiratory agents, diuretics, calcium antagonists, hormonal contraceptives, and others. Lipid regulators are medications designed to manage and control lipid levels in the body, including cholesterol and triglycerides. They are employed in treating various conditions such as hypercholesterolemia, hypertriglyceridemia, coronary artery disease, among others. These medications can be administered orally or via injection, and they find applications in pharmaceuticals, vaccines and drugs, scientific research, nutrition and supplements, food and beverages, and other sectors.

The lipid regulator market research report is one of a series of new reports from The Business Research Company that provides lipid regulator market statistics, including the lipid regulator industry global market size, regional shares, competitors with lipid regulator market share, detailed lipid regulator market segments, market trends, and opportunities, and any further data you may need to thrive in the lipid regulator industry. These lipid regulator market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lipid regulators market size has grown strongly in recent years. It will grow from $7.29 billion in 2024 to $7.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the increased prevalence of lifestyle diseases, growth in aging population, increased awareness of lipid regulators, increased healthcare expenditure, increased focus on healthcare prevention.

The lipid regulators market size is expected to see strong growth in the next few years. It will grow to $10.2 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, rising incidence of atherosclerosis with aging, increasing obesity rates, the rising prevalence of metabolic syndrome, growing focus on personalized medicine. Major trends in the forecast period include advancements in drug development, integration of digital health solutions, adoption of value-based pricing models, increase demand for over-the-counter, enhancing patient-cantered medication.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the angina pectoris drug market in the future. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, such as coronary artery disease, high blood pressure, heart failure, and stroke. The rise in cardiovascular diseases (CVD) can be attributed to factors like an aging population, unhealthy lifestyles, and the obesity epidemic. High cholesterol leads to atherosclerosis, a condition where arteries become hardened and narrowed due to plaque buildup, and lipid regulators play a crucial role in preventing its progression, thereby reducing the risk of heart attacks and strokes. For example, according to data from the British Heart Foundation, a UK-based cardiovascular research charity, approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with around 4 million men and 3.6 million women living with these conditions. These diseases account for about 27% of all deaths in the UK, leading to more than 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. As a result, the rising prevalence of cardiovascular diseases is fueling the growth of the angina pectoris drug market.

Leading companies in the lipid regulator market are actively developing advanced oral lipid-lowering medications to address high low-density lipoprotein (LDL) cholesterol levels in patients with heart conditions. These oral medications are targeted at individuals with inherited genetic abnormalities causing high cholesterol or those diagnosed with heart disease. For example, in May 2022, Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company based in India, introduced Bempedoic Acid Brillo in India, an oral medication designed to provide innovative therapy for high LDL cholesterol levels in cardiac patients. Bempedoic acid exerts a dual mode of action by inhibiting ATP citrate lyase, an enzyme involved in cholesterol production, and activating AMP-activated protein kinase (AMPK), which regulates cholesterol synthesis in the liver. Its once-daily oral administration offers enhanced convenience for patients compared to certain other cholesterol-lowering medications.

In April 2023, Luye Pharma Group, a pharmaceutical company based in China, entered into a partnership with Duopharma Marketing Sdn Bhd with the objective of leveraging Duopharma Biotech's cardiovascular expertise and Luye Pharma's advanced technology to market and distribute a traditional Chinese medicine utilizing innovative fermentation techniques. This medicine harnesses unique red yeast rice to effectively manage cholesterol levels. Duopharma Marketing Sdn Bhd, a subsidiary of Duopharma Biotech Berhad (Duopharma Biotech), specializes in the manufacture of lipid regulators and cholesterol-lowering agents in Malaysia.

Major companies operating in the lipid regulators market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Limited, Dr. Reddy's Laboratories Ltd., Biocon Ltd., Alnylam Pharmaceuticals Inc., Amarin Corporation plc, Arrowhead Pharmaceuticals Inc., Kowa Pharmaceuticals America Inc., Esperion Therapeutics Inc., Bentley Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Andrx Corporation

North America was the largest region in the lipid regulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid regulators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lipid regulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The lipid regulators market consists of sales of ezetimibe, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lipid Regulators Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lipid regulators market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lipid regulators ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lipid regulators market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Lipid Regulators; Narcotic Analgesics; Angiotensin Converting Enzyme (ACE) Inhibitors; Respiratory Agents; Diuretics; Calcium Antagonists; Hormonal Contraceptives; Other Types
• 2) By Indication: Hypercholesterolemia; Hypertriglyceridemia; Coronary Artery Disease; Other Indications
• 3) By Administration: Oral; Injectable
• 4) By Application: Pharmaceuticals; Vaccines And Drugs; Scientific Research; Nutrition And Supplements; Food And Beverages; Other Applications
• Subsegments:
• 1) By Lipid Regulators: Statins; Fibrates; Niacin; Omega-3 Fatty Acids
• 2) By Narcotic Analgesics: Opioid Analgesics; Combination Analgesics (Opioid And Non-opioid); Antagonists For Pain Relief
• 3) By Angiotensin Converting Enzyme (ACE) Inhibitors: Captopril; Enalapril; Lisinopril; Ramipril
• 4) By Respiratory Agents: Bronchodilators; Corticosteroids; Antihistamines
• 5) By Diuretics: Thiazide Diuretics; Loop Diuretics; Potassium-Sparing Diuretics
• 6) By Calcium Antagonists: Dihydropyridines; Non-Dihydropyridines
• 7) By Hormonal Contraceptives: Oral Contraceptives; Injectable Contraceptives; Implantable Contraceptives
• 8) By Other Types: Beta Blockers; Anticoagulants; Antiplatelets
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi SA; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lipid Regulators Market Characteristics

3. Lipid Regulators Market Trends And Strategies

4. Lipid Regulators Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Lipid Regulators Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lipid Regulators PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lipid Regulators Market Growth Rate Analysis
• 5.4. Global Lipid Regulators Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lipid Regulators Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lipid Regulators Total Addressable Market (TAM)

6. Lipid Regulators Market Segmentation

• 6.1. Global Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lipid Regulators
• Narcotic Analgesics
• Angiotensin Converting Enzyme (ACE) Inhibitors
• Respiratory Agents
• Diuretics
• Calcium Antagonists
• Hormonal Contraceptives
• Other Types
• 6.2. Global Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypercholesterolemia
• Hypertriglyceridemia
• Coronary Artery Disease
• Other Indications
• 6.3. Global Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Lipid Regulators Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceuticals
• Vaccines And Drugs
• Scientific Research
• Nutrition And Supplements
• Food And Beverages
• Other Applications
• 6.5. Global Lipid Regulators Market, Sub-Segmentation Of Lipid Regulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Fibrates
• Niacin
• Omega-3 Fatty Acids
• 6.6. Global Lipid Regulators Market, Sub-Segmentation Of Narcotic Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Opioid Analgesics
• Combination Analgesics (Opioid And Non-opioid)
• Antagonists For Pain Relief
• 6.7. Global Lipid Regulators Market, Sub-Segmentation Of Angiotensin Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Captopril
• Enalapril
• Lisinopril
• Ramipril
• 6.8. Global Lipid Regulators Market, Sub-Segmentation Of Respiratory Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bronchodilators
• Corticosteroids
• Antihistamines
• 6.9. Global Lipid Regulators Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thiazide Diuretics
• Loop Diuretics
• Potassium-Sparing Diuretics
• 6.10. Global Lipid Regulators Market, Sub-Segmentation Of Calcium Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dihydropyridines
• Non-Dihydropyridines
• 6.11. Global Lipid Regulators Market, Sub-Segmentation Of Hormonal Contraceptives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Contraceptives
• Injectable Contraceptives
• Implantable Contraceptives
• 6.12. Global Lipid Regulators Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Blockers
• Anticoagulants
• Antiplatelets

7. Lipid Regulators Market Regional And Country Analysis

• 7.1. Global Lipid Regulators Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lipid Regulators Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lipid Regulators Market

• 8.1. Asia-Pacific Lipid Regulators Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lipid Regulators Market

• 9.1. China Lipid Regulators Market Overview
• 9.2. China Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lipid Regulators Market

• 10.1. India Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lipid Regulators Market

• 11.1. Japan Lipid Regulators Market Overview
• 11.2. Japan Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lipid Regulators Market

• 12.1. Australia Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lipid Regulators Market

• 13.1. Indonesia Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lipid Regulators Market

• 14.1. South Korea Lipid Regulators Market Overview
• 14.2. South Korea Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lipid Regulators Market

• 15.1. Western Europe Lipid Regulators Market Overview
• 15.2. Western Europe Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lipid Regulators Market

• 16.1. UK Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lipid Regulators Market

• 17.1. Germany Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lipid Regulators Market

• 18.1. France Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lipid Regulators Market

• 19.1. Italy Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lipid Regulators Market

• 20.1. Spain Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lipid Regulators Market

• 21.1. Eastern Europe Lipid Regulators Market Overview
• 21.2. Eastern Europe Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lipid Regulators Market

• 22.1. Russia Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lipid Regulators Market

• 23.1. North America Lipid Regulators Market Overview
• 23.2. North America Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lipid Regulators Market

• 24.1. USA Lipid Regulators Market Overview
• 24.2. USA Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lipid Regulators Market

• 25.1. Canada Lipid Regulators Market Overview
• 25.2. Canada Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lipid Regulators Market

• 26.1. South America Lipid Regulators Market Overview
• 26.2. South America Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lipid Regulators Market

• 27.1. Brazil Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lipid Regulators Market

• 28.1. Middle East Lipid Regulators Market Overview
• 28.2. Middle East Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lipid Regulators Market

• 29.1. Africa Lipid Regulators Market Overview
• 29.2. Africa Lipid Regulators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lipid Regulators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lipid Regulators Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lipid Regulators Market Competitive Landscape And Company Profiles

• 30.1. Lipid Regulators Market Competitive Landscape
• 30.2. Lipid Regulators Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Lipid Regulators Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Abbott Laboratories
• 31.3. Novartis AG
• 31.4. Amgen Inc.
• 31.5. Merck KGaA
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Hetero Drugs Limited
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Biocon Ltd.
• 31.13. Alnylam Pharmaceuticals Inc.
• 31.14. Amarin Corporation plc
• 31.15. Arrowhead Pharmaceuticals Inc.

32. Global Lipid Regulators Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lipid Regulators Market

34. Recent Developments In The Lipid Regulators Market

35. Lipid Regulators Market High Potential Countries, Segments and Strategies

• 35.1 Lipid Regulators Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lipid Regulators Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lipid Regulators Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer